Endocrine Abstracts

Objectives: aGLP1 have been positioned as an effective and safe treatment in patients with Type 2 Diabetes Mellitus (DM2). The objective was to evaluate the changes metabolic and body composition at 6 months after initiation with Semaglutide weekly subcutaneous added to its basic treatment in patients with DM2.Material and Methods: Prospective observational study. Treatment was started in 42 patients with DM2, with weekly subcutaneous Semaglutide with a ...

Objectives: Assess the canagliflozin effect on the ABPI in patients without previous treatment with iSGLT-2 as a possible etiology of tissue hypoperfusion and a risk factor for amputations.Material and methods: Prospective observational study where we analyzed patients diagnosed of type 2 diabetes mellitus (DM2) with poor metabolic control and without prior treatment with iSGLT-2, which is initiated treatment with canagliflozin. Clinical, biochemical par...